ConductScience.org, home

Paper36923571

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.

Gillies H and 9 others. ERJ Open Res, 2023. Cited by 24 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study. Papers, record 36923571. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923571

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.
PubMed
Journal
ERJ Open Res
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
24
iCite
Relative citation ratio, by iCite
2.7
iCite
Revised in PubMed
2023-03-16
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gillies HHunter
2Niven RRalph
3Dake BTBenjamin T
4Chakinala MMMurali M
5Feldman JPJeremy P
6Hill NSNicholas S
7Hoeper MMMarius Mhttps://orcid.org/0000-0001-9086-2293
8Humbert MMarchttps://orcid.org/0000-0003-0703-2892
9McLaughlin VVVallerie V
10Kankam MMartin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05036135A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126210752Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.J Heart Lung Transplant2015https://conductscience.org/library/papers/26210752PubMed
234002056Kinase drug discovery 20 years after imatinib: progress and future directions.Nat Rev Drug Discov2021https://conductscience.org/library/papers/34002056PubMed
334425071Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Respir Med2022https://conductscience.org/library/papers/34425071PubMed
431709514Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction.Br J Pharmacol2021https://conductscience.org/library/papers/31709514PubMed
521471108C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/21471108PubMed
629280349Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.CPT Pharmacometrics Syst Pharmacol2018https://conductscience.org/library/papers/29280349PubMed
727286723A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.Clin Pharmacokinet2016https://conductscience.org/library/papers/27286723PubMed
831339889Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation.PLoS One2019https://conductscience.org/library/papers/31339889PubMed
924963404Imatinib: a breakthrough of targeted therapy in cancer.Chemother Res Pract2014https://conductscience.org/library/papers/24963404PubMed
1020010555A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.Clin Pharmacol Ther2010https://conductscience.org/library/papers/20010555PubMed
1121378262Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.Am J Respir Cell Mol Biol2011https://conductscience.org/library/papers/21378262PubMed
1226284693Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.Am J Hematol2015https://conductscience.org/library/papers/26284693PubMed
1332417272Pulmonary arterial hypertension specific therapy: The old and the new.Pharmacol Ther2020https://conductscience.org/library/papers/32417272PubMed
1425902888Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.Int Heart J2015https://conductscience.org/library/papers/25902888PubMed
1526070575Inhaled Therapies for Pulmonary Hypertension.Respir Care2015https://conductscience.org/library/papers/26070575PubMed
1621376411Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.Int J Cardiol2012https://conductscience.org/library/papers/21376411PubMed
1731813986Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator.Cardiovasc Res2020https://conductscience.org/library/papers/31813986PubMed
188548747Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.Cancer Res1996https://conductscience.org/library/papers/8548747PubMed
1922037378Comprehensive analysis of kinase inhibitor selectivity.Nat Biotechnol2011https://conductscience.org/library/papers/22037378PubMed
2020581169Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.Am J Respir Crit Care Med2010https://conductscience.org/library/papers/20581169PubMed

See all 38 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 24 citations.

PMIDTitleJournalYearIn PapersSource
41949976Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.Can Respir J2026https://conductscience.org/library/papers/41949976PubMed
40728162Novel Insights Into Receptor Tyrosine Kinases in Pulmonary Arterial Hypertension.J Am Heart Assoc2025https://conductscience.org/library/papers/40728162PubMed
40722843State of the Art in Pulmonary Arterial Hypertension: Molecular Basis, Imaging Modalities, and Right Heart Failure Treatment.Biomedicines2025https://conductscience.org/library/papers/40722843PubMed
40437342Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension.Clin Pharmacokinet2025https://conductscience.org/library/papers/40437342PubMed
40410529Cardiovascular inhalation for targeted drug delivery in cardiac disease.Heart Fail Rev2025https://conductscience.org/library/papers/40410529PubMed
40371062Sudden cardiac death in congenital heart disease-a narrative review and update.Front Cardiovasc Med2025https://conductscience.org/library/papers/40371062PubMed
39684570Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.Int J Mol Sci2024https://conductscience.org/library/papers/39684570PubMed
39112561Mechanisms and treatment of pulmonary arterial hypertension.Nat Rev Cardiol2025https://conductscience.org/library/papers/39112561PubMed
38532768IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.Pulm Circ2024https://conductscience.org/library/papers/38532768PubMed
38495664Pulmonary Hypertension in Women.Methodist Debakey Cardiovasc J2024https://conductscience.org/library/papers/38495664PubMed
37628831Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension.Int J Mol Sci2023https://conductscience.org/library/papers/37628831PubMed
37486563Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.Curr Heart Fail Rep2023https://conductscience.org/library/papers/37486563PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
EGF1950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
FGF22247PubTator's text mininghttps://conductscience.org/library/genes/2247NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
SRC6714PubTator's text mininghttps://conductscience.org/library/genes/6714NCBI Gene
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
IMATINIBCHEMBL941Derived from the trial1https://conductscience.org/library/drugs/CHEMBL941

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36923571

GET https://conductscience.org/api/papers/v1/36923571/references?page=2